Latest Period
Q2 2026
Security Snapshot
Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) Institutional Ownership
CUSIP: 92511W207
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
43
Shares (Excl. Options)
4,662,624
Price
$6.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- VRCA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 4,662,624
- Total 13F value
- $28,534,954
- Portfolio coverage rank
- 0%
- Share change
- -115,447
- Value change
- -$445,500
- Number of holders
- 43
- Shares outstanding
- 8,810,762
- SEC-reported price per share
- $5.94
- Insider filing price
- $5.94
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 92511W207.
- 43 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 39 to 43 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $25,275,078 to $28,534,954.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 43 institutions filings for Q2 2026.
Security key
92511W207
Latest holder period
Q2 2026
13F holders
43
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
VRCA full holder history
Verrica Pharmaceuticals Inc. SEC filings
Verrica Pharmaceuticals Inc. company facts
Verrica Pharmaceuticals Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92511W207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
VRCA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Manning Paul B | 50% | $28,437,789 | 8,056,031 | Paul B Manning | 25 Nov 2025 | |||
| Caligan Partners LP | 10% | 0% | $43,635,492 | 6,503,054 | 0% | Caligan Partners LP | 26 Dec 2025 | |
| Affinity Asset Advisors, LLC | 5.5% | +0.6% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| ARMISTICE CAPITAL, LLC | 5% | -25% | $3,649,153 | -$1,656,149 | 439,657 | -31% | Armistice Capital, LLC | 31 Dec 2025 |
As of 30 Jun 2026, 43 institutional investors reported holding 4,662,624 shares of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA). This represents 53% of the company’s total 8,810,762 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
53%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Caligan Partners LP | 10% | 923,910 | 0% | 0.27% | $5,654,329 |
| CANNELL CAPITAL LLC | 8.9% | 783,923 | +14% | 3.3% | $4,797,609 |
| Affinity Asset Advisors, LLC | 8% | 707,338 | 0% | 0.21% | $4,328,909 |
| Velan Capital Investment Management LP | 5.4% | 471,559 | 0% | 1.8% | $2,885,941 |
| ARMISTICE CAPITAL, LLC | 4.8% | 426,304 | -18% | 0.07% | $2,608,980 |
| BOOTHBAY FUND MANAGEMENT, LLC | 3.2% | 280,734 | 0% | 0.03% | $1,718,092 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 279,310 | +48% | 0% | $1,709,377 |
| Mariner, LLC | 2.4% | 207,230 | +744% | 0% | $1,268,247 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 138,160 | -0.54% | 0% | $845,656 |
| BlackRock, Inc. | 0.84% | 74,344 | +93% | 0% | $454,986 |
| VANGUARD FIDUCIARY TRUST CO | 0.8% | 70,173 | +7.8% | 0% | $429,459 |
| TWO SIGMA INVESTMENTS, LP | 0.46% | 40,825 | -19% | 0% | $249,849 |
| STATE STREET CORP | 0.33% | 28,916 | 0% | 0% | $176,966 |
| NORTHERN TRUST CORP | 0.31% | 26,996 | -15% | 0% | $165,216 |
| DAFNA Capital Management LLC | 0.27% | 23,750 | -85% | 0.03% | $145,350 |
| JANE STREET GROUP, LLC | 0.27% | 23,654 | -52% | 0% | $144,762 |
| Verdad Advisers, LP | 0.26% | 23,069 | +91% | 0.14% | $141,182 |
| RENAISSANCE TECHNOLOGIES LLC | 0.25% | 21,769 | -33% | 0% | $133,226 |
| Legacy Trust | 0.19% | 16,584 | -3.8% | 0.02% | $101,494 |
| FIFTH THIRD BANCORP | 0.16% | 14,000 | 0% | $85,680 | |
| DIMENSIONAL FUND ADVISORS LP | 0.16% | 13,888 | 0% | $84,995 | |
| XTX Topco Ltd | 0.16% | 13,723 | 0% | $83,985 | |
| TWO SIGMA SECURITIES, LLC | 0.15% | 13,045 | 0.01% | $79,835 | |
| HRT FINANCIAL LP | 0.15% | 13,023 | 0% | $79,000 | |
| BECK MACK & OLIVER LLC | 0.14% | 12,000 | 0% | 0% | $73,440 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 4,662,624 | $28,534,954 | -$445,500 | $6.12 | 43 |
| 2026 Q1 | 4,777,869 | $25,275,078 | -$4,207,213 | $5.29 | 39 |
| 2025 Q4 | 5,196,096 | $43,155,907 | +$20,755,741 | $8.31 | 49 |
| 2025 Q3 | 2,468,945 | $10,583,119 | +$10,479,755 | $4.31 | 31 |
| 2025 Q2 | 194,004 | $102,830 | +$102,830 | $0.53 | 4 |